Patient P-01810
Synthetic patientNBL-101 · Day 120 · 35–44 · F · baseline S05Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
88%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S05
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
- Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 62 ME-01 recommended — Monitoring Escalation ME-01
- Day 63 Patient accepted — Started ME-01 in the companion
- Day 66 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 45.
Primary contributors, last 14 days
- Inflammatory activity+8
- Toxicity+6
- Treatment adherence-4
- Nutritional resilience-3
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −12%
- Monitoring Escalation ME-01Day 62Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
87%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion64.6/100
stable · -0.6 vs previous 14 d
Toxicity
Blood55.7/100
worsening · +6.5 vs previous 14 d
Sleep quality
Wearable8/100
worsening · -3.0 vs previous 14 d
Energy level
Daily log1.2/10
worsening · -0.4 vs previous 14 d
Stress level
Daily log7.2/10
stable · +0.1 vs previous 14 d
Steps
Wearable2,425
improving · +310 vs previous 14 d
Adherence
Companion44.1 %
stable · -1.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 19 from the failing basin, 73 from restoration.
Would help
- GI-04 GI Support Protocol73% improved among 124 similar · onset 8 d · confidence 90%
- SC-12 Supportive Compound76% improved among 51 similar · onset 6 d · confidence 73%
- CR-01 Clinician Review100% improved among 8 similar · onset 5 d · confidence 73%
- More fibreGI -2.8 next day on high-intake days · n 15
Would not help
- Keep simple carbs lowGI +3.6 next day on high-intake days · n 20
- Keep fat lowGI +3.2 next day on high-intake days · n 22
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Simple carbohydrates+3.6detractor · 79%
- Dietary fat load+3.2detractor · 76%
- Insoluble fibre-2.8supporter · 63%
- Spicy / capsaicin-2.3no signal · 42%
- Alcohol-0.1no signal · 15%
- Histamine load0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 65
- WearableHRV 26 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 79 bpm
- Wearable2,425 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 65 and rising
- WearableSleep 5.1 h, below personal baseline
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 56
- Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 48/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 26 ms
- Sleep
- 5.6 h
- Steps
- 1,520
- Resting HR
- 80 bpm
Daily log: GI score 65, nutritional resilience 36, adherence 44.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.